Another amazing presence for Wyss Zurich startups at the 15th TOP 100 Swiss Startup Award!

The International Data Safety Monitoring Board has recommended the continuation of MUVON Therapeutic AG’s SUISSE MPC2 study, an indication that the startup is on schedule for the release of the final data and completion of the phase II study scheduled for Q3 2025.

With its therapy rooted in tissue engineering, MUVON Therapeutics AG is developing a low-risk, minimally invasive treatment that uses the patient’s own muscle precursor cells (MPC) to regenerate the damaged sphincter muscle to treat stress urinary incontinence (SUI).

Discover the world shapers of tomorrow.

MUVON Therapeutics AG was featured in a recent publication in Nature Biotechnology. (Image credit: Nature Biotechnology)

Our project leader Deana Mohr-Haralampieva of MUVON published an article in the medical journal, Leading Opinions: Gynäkologie & Geburtshilfe, a Universimed publication.

This September, the Female Innovation Forum (FIF) took place for the sixth time at the BMW Group Brand Experience Center in Dielsdorf. Jenny Prange and Deana Mohr from the biotech startup “MUVON” won the “Female Innovator of the Year” award. Dörte Welti sat down with them to have a chat about their experiences as award winners and entrepreneurs.

The “Female Innovator of the Year” award went to Deana Mohr (CEO) and Jenny Prange (CTO) from MUVON Therapeutics.

Fantastic presence of current and alumni Wyss Zurich projects at TOP 100 Swiss Startup Award! ANYbotics (ANYmotion) and CUTISS (denovoSkin) again first respectively on Robotics and Biotech Scale-up ranking, MUVON positioned at the top among the fourty-one newcomers and made the third place on Biotech Startup ranking.